These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35535222)

  • 41. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis.
    Kraft P; Schwarz T; Göb E; Heydenreich N; Brede M; Meuth SG; Kleinschnitz C
    Exp Neurol; 2013 Sep; 247():80-90. PubMed ID: 23570902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
    Takano A; Uz T; Garcia-Segovia J; Tsai M; Lahu G; Amini N; Nakao R; Jia Z; Halldin C
    Mol Imaging Biol; 2018 Aug; 20(4):615-622. PubMed ID: 29441434
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects.
    Guo H; Cheng Y; Wang C; Wu J; Zou Z; Niu B; Yu H; Wang H; Xu J
    Neuropharmacology; 2017 Apr; 116():260-269. PubMed ID: 28065587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity.
    Aoki M; Kobayashi M; Ishikawa J; Saita Y; Terai Y; Takayama K; Miyata K; Yamada T
    J Pharmacol Exp Ther; 2000 Oct; 295(1):255-60. PubMed ID: 10991987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder.
    Wang Z; Liang Y; Zhang L; Zhang N; Liu Q; Wang Z
    Aging (Albany NY); 2018 Sep; 10(9):2394-2406. PubMed ID: 30227388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of phosphodiesterase-4 reverses the cognitive dysfunction and oxidative stress induced by Aβ25-35 in rats.
    Zhuo Y; Guo H; Cheng Y; Wang C; Wang C; Wu J; Zou Z; Gan D; Li Y; Xu J
    Metab Brain Dis; 2016 Aug; 31(4):779-91. PubMed ID: 26920899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
    Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
    Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
    Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
    J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
    Kanes SJ; Tokarczyk J; Siegel SJ; Bilker W; Abel T; Kelly MP
    Neuroscience; 2007 Jan; 144(1):239-46. PubMed ID: 17081698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice.
    Lipina TV; Wang M; Liu F; Roder JC
    Neuropharmacology; 2012 Mar; 62(3):1252-62. PubMed ID: 21376063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.
    Schaal SM; Garg MS; Ghosh M; Lovera L; Lopez M; Patel M; Louro J; Patel S; Tuesta L; Chan WM; Pearse DD
    PLoS One; 2012; 7(9):e43634. PubMed ID: 23028463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase-1 by a mechanism dependent on MAP kinase phosphatase-1.
    Tuure L; Hämäläinen M; Moilanen E
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of a column-switching high-performance liquid chromatography method to assess the presence of specific binding of (R)- and (S)-[(11)C]rolipram and their labeled metabolites to the phosphodiesterase-4 enzyme in rat plasma and tissues.
    Kenk M; Greene M; Lortie M; Dekemp RA; Beanlands RS; Dasilva JN
    Nucl Med Biol; 2008 May; 35(4):515-21. PubMed ID: 18482689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
    Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of Novel 3-Amino-4-alkoxyphenylketones as PDE4 Inhibitors with Improved Oral Bioavailability and Safety against Spatial Memory Impairments.
    Xia C; He JP; Feng KW; Liu L; Zheng L; Wang HT; Xu JP; Zhou ZZ
    ACS Chem Neurosci; 2022 Feb; 13(3):390-405. PubMed ID: 35050567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
    Thevis M; Krug O; Schänzer W
    Rapid Commun Mass Spectrom; 2013 May; 27(9):993-1004. PubMed ID: 23592202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of phosphodiesterase 4 enhances clitoral and vaginal blood flow responses to dorsal clitoral nerve stimulation or PGE1 in anesthetized female rats.
    Castiglione F; Bergamini A; Russo A; La Croce G; Castagna G; Colciago G; Salonia A; Rigatti P; Montorsi F; Hedlund P
    J Sex Med; 2013 Apr; 10(4):939-50. PubMed ID: 23347325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium.
    Galindo-Tovar A; Vargas ML; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Apr; 379(4):379-84. PubMed ID: 19005642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
    Liang J; Huang YY; Zhou Q; Gao Y; Li Z; Wu D; Yu S; Guo L; Chen Z; Huang L; Liang SH; He X; Wu R; Luo HB
    J Med Chem; 2020 Mar; 63(6):3370-3380. PubMed ID: 32115956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse.
    Sun X; Liu Y; Liu B; Xiao Z; Zhang L
    Exp Neurol; 2012 Oct; 237(2):304-11. PubMed ID: 22836144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.